Shots:

• The P-III RUXCOVID study will assess Jakavi + SOC vs SOC as monothx. in patients with severe COVID-19 as a result of SARS-CoV-2 infection. The collaborative study will be sponsored by Incyte in the US and Novartis outside the US
• The decision is based on preclinical evidence and preliminary reports from independent studies and is supported by data on the safety and efficacy of Jakavi in acute GVHD and MPNs. Additionally- Incyte intends to commence an open-label emergency Expanded Access Program (EAP) in the US to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib
• Novartis will establish an international compassionate use program for COVID-19 patient access to ensure no disruption in the supply of Jakavi for currently licensed indications. Jakavi (ruxolitinib) is JAK 1 & 2 tyrosine kinases inhibitor and is an approved therapy in 101 countries for patients with MF and 75+ countries for PV

Source 1- Source 2 ­to­ read full press release/ article 

Ref: Novartis- Incyte | Image: Novartis